Xcout IntelCombined Therapeutics, Inc.
Combined Therapeutics is a biotechnology company that develops next-generation mRNA vaccines and immunotherapies for infectious diseases and oncology. The company utilizes a proprietary mRNA platform featuring microRNA binding sequences to target therapeutic protein expression in specific tissues while protecting vital organs from off-target effects.
Subscribe to see Combined Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Combined Therapeutics, Inc. at a glance
Combined Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Early Funding, closed in March 2023. Xcout tracks 8 named people at Combined Therapeutics, Inc., including Carol Walton (Chief Business Development Officer).
Combined Therapeutics, Inc. leadership
- Carol WaltonChief Business Development Officer
- Romain MicolPresident and Chief Executive Officer (co-founder), Board Director
- Dan AndersonCo-founder
- Robert LangerCo-founder
- Valerie DuvalDirector, Molecular Biology and mRNA Platform Development
- Paul WottonBoard Director
2 more named people on record for Combined Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Combined Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Early Funding | Undisclosed | — | |
| Series A | $20M | — | |
| SEC Form D filing | $250,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Combined Therapeutics, Inc. competitors
A few of Combined Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Xanadu Bio, Inc. is a biotechnology company that develops next-generation polymer nanoparticle delivery platforms for mRNA and other nucleic acid-based therapies. Utilizing its proprietary poly(amine-co-ester) (PACE) polymer technology, the company creates tunable, organ-specific treatments for oncology and immunology, as well as intranasal vaccines for viral respiratory pathogens.
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
CHARM Therapeutics Inc. is a biopharmaceutical company utilizing proprietary technology platforms for drug discovery and therapeutic pipeline development.
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
RNAV8 Bio is a biotechnology research company focused on renovating mRNA function through structure, chemistry, and delivery.
Catena Biosciences is a biotechnology company based in Berkeley, California, that pioneers protein conjugation technologies for novel therapeutics. Founded in 2020, the company builds upon technology developed in labs at the University of California, Berkeley.
Get Combined Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Combined Therapeutics, Inc. in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access